Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31304657 | 1.00 | LPL (0.42) | LPLLIPGPRMT5WDR77PARP1 | |
| SCHEMBL31023038 | 0.88 | PRMT5 (0.41) | LPLLIPGPRMT5WDR77PARP1 | |
| SCHEMBL2172042 | 0.88 | PRMT5 (0.41) | LPLLIPGPRMT5WDR77PARP1 | |
| SCHEMBL29513455 | 0.78 | LPL (0.46) | LPLLIPGIRAK4 | |
| SCHEMBL13718 | 0.78 | LPL (0.46) | LPLLIPGIRAK4 | |
| SCHEMBL1629562 | 0.77 | LPL (0.51) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL392405 | 0.77 | PRMT5 (0.47) | LPLLIPGPRMT5WDR77PARP1 | |
| SCHEMBL27159644 | 0.75 | PRMT5 (0.46) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL29914854 | 0.75 | PRMT5 (0.46) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL29914853 | 0.75 | PRMT5 (0.46) | LPLLIPGPRMT5WDR77IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220235087-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. | 2022-07-28 | — | — | US | disclosed |
| US-20200407390-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10738070-B2 | Mannose-derived antagonists of FimH useful for treating disease | FIMBRION THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-10738070-B2 | Mannose-derived antagonists of FimH useful for treating disease | FIMBRION THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190106451-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | CLIMATE LLC | 2019-04-11 | — | — | US | disclosed |
| US-20190106451-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | CLIMATE LLC | 2019-04-11 | — | — | US | disclosed |
| EP-3432892-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | Fimbrion Therapeutics, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-3426260-A1 | C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE | Fimbrion Therapeutics, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017165619-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017165619-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017156508-A1 | C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156508-A1 | C-GLYCOSIDE COMPOUNDS USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407390-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | LPL 3014/4885LIPG 1960/4885PRMT5 1974/4885 |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | LPL 535/4885LIPG 291/4885PRMT5 566/4885 |
| US-20220235087-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | LPL 3014/4885LIPG 1960/4885PRMT5 1974/4885 |
| US-10738070-B2 | Mannose-derived antagonists of FimH useful for treating disease | MAN2B2, MAN2A1, MANBA | LPL 3014/4885LIPG 1960/4885PRMT5 1974/4885 |
| US-20190106451-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | LPL 3014/4885LIPG 1960/4885PRMT5 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.